Areas of Research
The aim of the Green Laboratory is to improve the survival and quality of life for people suffering from B-cell malignancies by developing innovative therapeutic interventions that are driven by deep mechanistic understanding of normal and malignant immune cell biology.
Our group takes a multi-disciplinary approach to understanding the pathophysiology of B-cell lymphoma. We integrate knowledge from cutting-edge ‘omics’ approaches, primary patient biopsies, patient-derived xenograft models, transgenic mouse models, cell lines and CRISPR/Cas9 gene editing experiments to characterize the function of important genetic, epigenetic and immunological alterations in B-cell lymphoma and its tumor microenvironment. Our goal is to harness this information to identify and develop new rationally targeted therapeutic strategies to improve the outcomes of patients with lymphoma.
Join Our Lab
We are always looking for motivated postdoctoral fellows (wet-lab and computational) to join a team that wants to make an impact.
We sincerely thank the following philanthropic donors for their generous support of our research:
- The Schweitzer Family
- The Futcher Family
- The Baer Family
- The Institute for Follicular Lymphoma Innovation (IFLI)
Career Development Support
- Michael Green, Ph.D., is supported by a Scholar Award from the Leukemia and Lymphoma Society
- Haopeng Yang, Ph.D., is supported by a Fellow Award from the Leukemia and Lymphoma Society
- Patrick Reville, M.D., is supported by a Postdoctoral Fellowship from the Lymphoma Research Foundation and a Young Investigator Award from the American Society of Clinical Oncology
Active Grant Funding
Identifying/targeting mechanisms of lymphomagenesis driven by CREBBP inactivation, R01CA201380, NIH/NCI, 2016-2027 (PI, Green)
Functional characterization and rational therapeutic targeting of 18q DNA copy number gains in diffuse large B-cell lymphoma, R01CA240839, NIH/NCI, 12/1/2020-11/30/2025 (PI, Green)
Roles of Coactivator-Associated Arginine Methyltransferase 1 in B cell activation and lymphomagenesis, NIH/NCI, R01CA247883, 04/2021-03/2026 (MPIs, Santos and Green)
Targeting Myeloid Cells to Mitigate Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-cell Lymphoma, NIH/NCI, R21CA259694, 05/01/2021-04/30/2023 (MPIs, Strati and Green)
Predicting Response and Improving Efficacy of CAR T-cell Therapy in DLBCL, RP200385, CPRIT, 09/2020-08/2023 (MPIs, Wang and Green)
Targeting SMARCA4 mutations in pediatric Burkitt Lymphoma, RP220208, CPRIT, 03/2022-02/2026 (PI, Green)
BAF complex deregulation in lymphoma, R01CA266279, NIH/NCI, 07/2022-06/2027 (MPIs, Green and Mason [Weill Cornell Medicine])